Titan Pharmaceuticals has agreed to a merger agreement with privately held Malaysian company KE Sdn. Bhd. The latter is known as a distributor of human capital management solutions.
The pharma's shares are up 100% in premarket trading Tuesday.
Titan will be combined with KE in a reverse merger. The deal still needs approval from stockholders of both companies.
Titan CEO and Board Chairman Dato’ Seow Gim Shen currently holds 47.4% of the outstanding shares of KE. After the merger, he will own 48.9% of the combined company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments